Cargando…
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven no...
Autores principales: | Aurilio, Gaetano, Cimadamore, Alessia, Santoni, Matteo, Nolè, Franco, Scarpelli, Marina, Massari, Francesco, Lopez-Beltran, Antonio, Cheng, Liang, Montironi, Rodolfo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349416/ https://www.ncbi.nlm.nih.gov/pubmed/32580469 http://dx.doi.org/10.3390/cells9061522 |
Ejemplares similares
-
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
por: Cimadamore, Alessia, et al.
Publicado: (2020) -
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
por: Montironi, Rodolfo, et al.
Publicado: (2020) -
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
por: Aurilio, Gaetano, et al.
Publicado: (2020) -
Narrative review: update on immunotherapy and pathological features in patients with bladder cancer
por: Aurilio, Gaetano, et al.
Publicado: (2021) -
Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
por: Cimadamore, Alessia, et al.
Publicado: (2021)